. . . . . . . . . "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved." . . . . . . "Adolescents (15-17)" . . "2021-08-24T16:13:47.586648"^^ . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" . "GqT07hBN6al0Vf9zMLUZYNzBCP2WgoGtVEi1VIIjzx7DszQkCsPChUxAeFYXFkkJTi/Z/qgmVFi2SvV79CLKc13RJvQXvBfyFBBGGGCFmfnKTMBESghqW8/+WwQLkPz6tOUzfoJxKW5+LWXCcq5p2gN+XVWWYcOk9CFa/O50QMs=" . . "2021-08-24T16:13:47.586648"^^ . . .